Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 1, 2007

BMS Signs Research Services Agreement with Immunicon for Oncology Biomarker Development

  • Immunicon entered into a research services agreement with Bristol-Myers Squibb involving protein and molecular targets associated with circulating tumor cells.

    “Our collaborations span across protein biomarkers, phosphoproteins, and a variety of FISH assays to study gene amplification in a number of different carcinomas. We believe that our development work will advance the understanding of cancer biology as well as accelerate the time to market for promising new drugs,” comments Leon Terstappen, M.D., Ph.D., CSO at Immunicon.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »